Insmed Incorporated
8720 Stony Point Parkway
Suite 200
Richmond,
VA 23235
United States - Map
Phone: 804-565-3000
Fax: 804-565-3500
Web Site: http://www.insmed.com
| Insmed Incorporated, a development stage company, engages in the development of recombinant protein drug. The companys primary product includes IPLEX, a complex of recombinant human IGF-1 and its binding protein IGFBP-3 for use in the treatment of several serious medical conditions, as well as conducting a phase III enabling clinical trial for investigating IPLEX as a treatment for myotonic muscular dystrophy. Insmed also engages in various oncology programs, including INSM-18, an orally available small molecule tyrosine kinase inhibitor that has demonstrated selective inhibition of IGF-1 and human epidermal growth factor receptor; and rhIGFBP-3, which is in early clinical development stage for the treatment of breast, prostate, liver, ovarian, and colon cancers. The company also provides Expanded Access Program in Italy to offer IPLEX to physicians for use in their patients with amyotrophic lateral sclerosis. It has a license to Pharmacia ABs portfolio of regulatory filings pertaining to rhIGF; and an agreement with NAPO Pharmaceuticals that gives NAPO the right to develop, manufacture, and commercialize masoprocal products for various indications relating to diabetes, cardiac disease, vascular disease, metabolic disease, and syndrome X. The company was founded in 1999 and is headquartered in Richmond, Virginia. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Kevin P. Tully C.G.A., 55
Chief Financial Officer, Principal Accounting Officer and Exec. VP |
$
360.00K |
$
3.00K | Mr. Steve Glover , 49
Chief Bus. Officer |
$
422.00K | N/A | Mr. Glen Kelley , 41
VP of Regulatory Affairs |
N/A
| N/A | Dr. Andreas Sommer Ph.D., 67
Chief Scientific Officer |
N/A
| N/A | Mr. W. McIlwaine Thompson Jr., 49
Sec. |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29%
Profile
